Company News for July 22, 2011

Zacks


•    BB&T Corp. (NYSE:BBT) reported Q2 EPS of $0.44, slightly above the Zacks Consensus Estimate of $0.42 per share. Revenues rose 7% year-over-year to $2.18 billion, beating the Zacks Consensus Estimate of $2.148 billion

•    WESCO International, Inc. (NYSE:WCC) reported Q2 EPS of $1.00, surpassing the Zacks Consensus Estimate of $0.92 per share. Revenues for the quarter rose 21.1% year-over-year to $1.52 billion

•    WNS Limited (NYSE:WNS) reported Q1 EPS of $0.22, beating the Zacks Consensus Estimate of $0.15 per share. Revenues for the quarter rose 9.5% year-over-year to $97.8 million, ahead of the Zacks Consensus Estimate of $94.0 million

•    Express Scripts, Inc. (NASDAQ:ESRX) reported Q2 EPS of $0.71, in line with the Zacks Consensus Estimate. However, revenues for the quarter rose 0.6% year-over-year to $11.36 billion, higher than the Zacks Consensus Estimate of $11.322 billion

•    Medco Health Solutions (NYSE:MHS) reported Q2 EPS of $0.96, marginally higher than the Zacks Consensus Estimate of $0.94 per share. Revenues for the quarter rose 3.5% year-over-year to $16.72 billion, lower than the Zacks Consensus Estimate of $17.086 billion

•    Reacting to news that SFN Group Inc. (NYSE:SFN) will be acquired by the Dutch company Randstad Holding for $770 million, share prices of SFN rose 51.08% a day to close at $13.93

•    Express Scripts Inc. (NASDAQ:ESRX) announced its decision to buy pharmacy-benefits manager Medco Health Solutions Inc (NYSE:MHS) in a deal valued at $29.1 billion in cash and stock

•    Shares of F5 Networks Inc. (NASDAQ:FFIV) fell 11.28% a day after the software company posted its earnings results for the third quarter that came in below expectations

•    Analysts at Robert W. Baird upgraded Robert Half Intl Inc. (NYSE:RHI) to an "Outperform" rating from a "Neutral" rating setting a target price of  $35.00 on the shares of the company

•    Morgan Keegan analysts initiated coverage on shares of Iridium Communications (NASDAQ:IRDM) with an "Outperform" rating and with a target price of $12.00

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)